United Therapeutics Corporation (UTHR) Stock Price, News, Analysis

Technical Score (1D)

SELL

News Sentiment

BULLISH

United Therapeutics’ FDA pre‑market approval of its LungFX ex‑vivo lung perfusion device is the headline change, confirming the company’s ability to bring a new platform to market. The approval follows encouraging phase‑3 results for Tyvaso in the TETON‑1 study, reinforcing the strength of UTHR’s therapeutic pipeline. Together, these developments suggest that UTHR could see a lift in revenue streams over the next 1–10 trading days as commercialization plans move forward. Insider selling under trading plans has been noted, but the company’s year‑to‑date return of 10% and 1‑year total shareholder return of 85% indicate that the market remains confident in the long‑term narrative. The FDA clearance is likely to increase investor expectations for near‑term earnings, so traders should watch for any guidance updates in the upcoming quarterly report. Pay particular attention to the company’s projected commercialization timeline for LungFX, as any delay could temper the upside. Also monitor for additional FDA filings or regulatory milestones that could further validate the product’s market readiness. Finally, keep an eye on Tyvaso’s commercial performance once it enters the market, as it will test the robustness of the positive phase‑3 data.

UTHR|Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NMS

Country

United States

Website

unither.com

Symbol

UTHR

Description

United Therapeutics Corporation is a biotechnology firm focused on commercializing therapies for chronic and life-threatening illnesses, primarily in the United States and internationally. The company's core business revolves around treatments for pulmonary arterial hypertension (PAH), offering a portfolio of approved products like Tyvaso DPI, Tyvaso, Remodulin, Orenitram, and Adcirca, designed to manage symptoms and slow disease progression. Beyond PAH, United Therapeutics markets Unituxin for high-risk neuroblastoma and is developing innovative therapies, including RemoPro, Ralinepag, and Aurora-GT, expanding its pipeline for PAH and other indications. Strategic collaborations with other entities, such as DEKA Research & Development Corp. and MannKind Corporation, support the company's efforts to enhance drug delivery and expand its product offerings. This focus on specialized therapies positions United Therapeutics to address unmet medical needs and improve patient outcomes.

UTHR|Earnings Snapshot

Earnings Summary

United Therapeutics Corporation is a biotechnology firm specializing in therapies for pulmonary arterial hypertension and other high‑margin indications, with a portfolio that includes Tyvaso, Remodulin, and Unituxin, and a growing pipeline of novel agents such as Ralinepag and Aurora‑GT. The company operates within the specialty drug manufacturing sector, focusing on niche, life‑saving treatments that command premium pricing. In Q4 2024 the company reported earnings per share of $6.19, slightly below the $6.27 estimate, while revenue rose to $735.9 million, a modest increase from prior periods but falling short of the $829.3 million estimate for Q4 2025; in that quarter EPS climbed to $7.70, surpassing the $7.33 estimate, yet revenue of $790.2 million again missed the $829.3 million forecast, indicating a pattern of earnings growth coupled with revenue shortfalls. Over the two quarters examined, EPS grew by roughly 25 % year‑over‑year, and revenue increased about 7 %, but the company has consistently beat or missed analyst expectations in alternating quarters, suggesting volatility in revenue forecasting while maintaining a positive earnings trajectory. Recent news highlights include a significant insider sale by the CEO, which may signal liquidity concerns or a shift in confidence, alongside robust clinical wins for Tyvaso and Ralinepag that reinforce growth expectations; the FDA pre‑market approval of the LungFX ex‑vivo perfusion system and the acquisition of Thymmune Therapeutics expand the company’s organ perfusion and regenerative medicine capabilities, potentially opening new revenue streams; and RBC Capital’s price‑target upgrade to $704 reflects renewed bullish sentiment tied to upcoming FDA filings for Ralinepag and Nebulized Tyvaso. Investors should watch for the Q2 2026 earnings release to assess whether the company can sustain its EPS growth trend, monitor any updates on FDA review progress for the new indications, and keep an eye on insider trading activity and regulatory milestones that could materially influence the company’s valuation and market perception.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$7.04	-	-
Q4'25	$7.33	$7.70	+5.1%
Q4'24	$6.27	$6.19	-1.2%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$824M	-	-
Q4'25	$829M	$790M	-4.7%
Q4'24	-	$736M	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

UTHR Stock Snapshot

UTHR is currently trading at $547.06, giving United Therapeutics Corporation a market cap of 23.22B and a P/E ratio of 18.0. Today's range spans $539.33–$553.86, with shares opening at $553.86 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 41/100 (HOLD) with a news sentiment reading of 84/100.

Over the past year UTHR has traded between $272.12 and $609.35 - the current price is +101.0% off the 52-week low and -10.2% from the high. 24 analysts cover the stock with a Buy consensus and a mean 12-month target of $664.00 (range $516.00–$750.00), implying upside of +21.4%.

United Therapeutics Corporation (UTHR) has 23.22B in Healthcare market capitalization and is currently neutral on the technical dashboard: 41/100, HOLD, price $547.06 (in the upper portion of its 52-week range). Sentiment reads bullish at 84/100. (P/E: 18.0) In this tier, quiet accumulation often happens in HOLD phases - active managers who want to build positions without signaling do it here, where the price isn't trending and volume patterns are easier to hide. Annual range: $272.12–$609.35.

In neutral phases, large-cap Healthcare names like UTHR are often where sector rotation debates play out quietly — at 23.22B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 41/100 (HOLD) and bullish sentiment (84/100) at $547.06 (in the upper portion of its 52-week range) describe a stock that is being considered rather than avoided.

News Sentiment Analysis

Sentiment gathered from recent headlines

84/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

United Therapeutics (UTHR) received FDA pre‑market approval for its LungFX ex‑vivo lung perfusion device, bolstering its growth narrative. The approval follows encouraging TETON‑1 phase‑3 results for Tyvaso, reinforcing the company’s portfolio strength. Despite recent insider selling under trading plans, the stock’s year‑to‑date return of 10% and 1‑year total shareholder return of 85% suggest sustained investor confidence. Traders should monitor the next quarterly earnings for updated guidance on LungFX commercialization and any further FDA filings.

What did this article say?

United Therapeutics (UTHR) successfully had its manufactured organs transported via the first operational flights of the U.S. DOT and FAA eVTOL Integration Pilot Program. The flights, conducted by BETA Technologies and the Multistate Collaborative, demonstrate the feasibility of using electric vertical takeoff and landing aircraft for critical medical logistics. This milestone supports UTHR’s strategy to expand rapid organ delivery across at least 26 states and could accelerate the company’s supply chain capabilities.

What did this article say?

BofA Securities reduced its price target for United Therapeutics from $620 to $613, reflecting modest concerns about the company’s near‑term earnings outlook. The downgrade signals a slight shift in analyst sentiment, potentially impacting investor expectations for the upcoming earnings cycle. Traders should monitor how the market reacts to this adjustment and assess the impact on UTHR’s valuation relative to peers.

What did this article say?

No summary available yet for this article.

What did this article say?

BETA Technologies completed its first FAA eIPP electric aircraft flights, transporting manufactured organs developed by United Therapeutics. The flights demonstrate the feasibility of using eVTOLs for medical logistics across at least 26 states. This milestone could expand UTHR's organ distribution capabilities and support its growth strategy. Traders should monitor UTHR's guidance on organ manufacturing and logistics integration, as well as potential regulatory approvals for eVTOL medical transport.

What did this article say?

United Therapeutics CEO Martine A. Rothblatt sold 9,500 shares worth approximately $5.2 million on July 9, 2026. The transaction raises questions about insider confidence in the company’s future prospects, though no explicit reason was disclosed. Investors should consider the potential impact on UTHR’s stock momentum and the broader market perception of leadership sentiment.

What did this article say?

On July 8, 2026, United Therapeutics CEO Martine A. Rothblatt sold 9,500 shares of UTHR worth $5.3 million, the largest insider transaction reported this year. The sale may signal a short‑term liquidity need or a shift in insider confidence, though no explicit rationale was provided. Investors should monitor whether additional insider activity follows and assess the potential impact on UTHR’s share price volatility.

What did this article say?

United Therapeutics’ 14% YTD performance is underpinned by major clinical breakthroughs, notably the positive TETON‑1 phase III results for idiopathic pulmonary fibrosis (IPF). The company is extending Tyvaso beyond approved PAH indications into larger IPF and progressive pulmonary fibrosis (PPF) markets, enhancing long‑term revenue prospects. Investors should keep an eye on forthcoming IPF data releases and Tyvaso expansion approvals.

What did this article say?

Insider Martine A Rothblatt sold 9,500 UTHR shares, totaling $5.3 million, on July 7, 2026. The transaction may suggest a shift in insider confidence or a strategic portfolio adjustment. It provides a benchmark for evaluating future insider activity. Traders should consider the sale in the context of upcoming earnings and regulatory developments.

What did this article say?

The FDA’s pre‑market approval of UTHR’s LungFX ex‑vivo lung perfusion system signals a key regulatory win for the company’s organ manufacturing strategy. UTHR’s recent acquisition of Thymmune Therapeutics adds regenerative thymic cell therapy technology that could enhance transplant tolerance and broaden its therapeutic pipeline. Together, these moves reinforce UTHR’s focus on centralized ex‑vivo organ perfusion and regenerative medicine. The company’s outlook now includes potential revenue streams from both LungFX commercialization and Thymmune’s clinical development.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

No summary available yet for this article.

What did this article say?

UTHR·United Therapeutics Corporation

EPS

Revenue

UTHR Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More